ArticleBlood cancer journal2025

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium.

Danai Dima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.